STOCK TITAN

Nutriband Announces USPTO Notice of Allowance for Commercial Brand Name Trademarks for Its Abuse-Deterrent Fentanyl Transdermal System

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Nutriband (NASDAQ:NTRB) received a USPTO Notice of Allowance for commercial brand name trademarks for its abuse-deterrent fentanyl transdermal system.

The notice is dated November 3, 2026. Nutriband intends to secure full trademark registration in the United States and internationally. It is preparing proposed global brand name submissions to the FDA, EMA and other international regulators through pathways allowing name review before formal drug approval applications. These are brand-name steps, not drug approval. The company estimates potential peak annual U.S. sales of $80 million to $200 million for the product, citing a 2022 market analysis.

Loading...
Loading translation...
3 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate point. Forward-looking: it has not happened yet and may not happen.Potential peak annual U.S. sales estimated by Nutriband at $80 million to $200 million.
  • Minor pointUSPTO Notice of Allowance received for the fentanyl system’s commercial brand name trademarks, dated November 3, 2026.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Trademark registration is planned in the United States and internationally.

Negative

  • Minor point. Forward-looking: it has not happened yet and may not happen.Full trademark registration remains a future step following the Notice of Allowance.
  • Minor pointRegulatory brand-name submissions remain in preparation for the FDA, EMA and other international agencies.

Key Figures

Notice of Allowance date: November 3, 2026 Potential peak annual U.S. sales: $80 million to $200 million
Notice of Allowance date
November 3, 2026
USPTO commercial brand name trademarks
Potential peak annual U.S. sales
$80 million to $200 million
Company-cited estimate for the abuse-deterrent fentanyl transdermal system

Key Terms

new drug application, marketing authorization application
2 terms
new drug application regulatory
"ahead of formal New Drug Application (NDA) or Marketing Authorization Application (MAA) filings"
A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.
marketing authorization application regulatory
"ahead of formal New Drug Application (NDA) or Marketing Authorization Application (MAA) filings"
A marketing authorization application is a formal request submitted to a government regulator asking permission to sell a prescription medicine or medical product in a country or region. Think of it like asking for a business license after showing evidence the product is safe and works; investors care because approval determines whether the product can generate sales, how soon revenue starts, and how much regulatory risk and uncertainty remains.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Preapproval regulatory submissions for the proposed global brand name are being prepared for the US FDA, EU EMA, and international agencies

ORLANDO, Fla., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB), a pharmaceutical company developing proprietary transdermal drug delivery systems, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO), dated November 3, 2026, for commercial brand name trademarks for its lead product, an abuse-deterrent fentanyl transdermal system. Nutriband intends to secure full trademark registration and intellectual property rights for its commercial brand names in the United States and internationally.

In developing the commercial brand name, extensive naming research was conducted to ensure physicians, pharmacists, and patients can clearly distinguish the proprietary name from existing medications with similar spellings, appearances, or pronunciations (look-alike/sound-alike names). Selecting a distinct, non-misleading brand name is a critical patient-safety measure designed to prevent dispensing errors and potential serious adverse medical outcomes.

The company is currently preparing to submit its proposed global brand name to the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other international regulatory bodies through dedicated preapproval pathways. These pathways allow regulators to review and approve a pharmaceutical brand name ahead of formal New Drug Application (NDA) or Marketing Authorization Application (MAA) filings.

Formulated with proprietary AVERSA™ technology, Nutriband’s lead product has the potential to become the world’s first transdermal fentanyl patch engineered to deter intentional abuse and misuse while reducing the risk of accidental exposure.

Nutriband’s abuse-deterrent fentanyl transdermal system has the potential to reach peak annual U.S. sales of between $80 million and $200 million.1 While initially concentrating on the U.S. market, the unmet medical need for adequate pain management is a global problem, and ongoing development is targeted at major medical markets worldwide.

Nutriband’s AVERSA™ abuse-deterrent technology is utilized to incorporate aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA™ abuse-deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.
__________________________________________________________________________

1 Health Advances Aversa Fentanyl market analysis report 2022

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who depend on them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband, Inc.

Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Nutriband is a registered trademark of Nutriband, Inc. AVERSA is a trademark of Nutriband, Inc.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com

SOURCE: Nutriband Inc.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What trademark milestone did Nutriband announce for its fentanyl patch?

Nutriband received a USPTO Notice of Allowance dated November 3, 2026, for commercial brand name trademarks for its abuse-deterrent fentanyl transdermal system. Full trademark registration remains an intended next step.

What are Nutriband’s next steps for its proposed fentanyl patch brand name?

Nutriband is preparing submissions to the FDA, EMA and other international regulatory bodies for its proposed global brand name. The preapproval pathways allow pharmaceutical name review and approval before formal New Drug Application or Marketing Authorization Application filings.

Keep reading